Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT05500586
PHASE1/PHASE2

The Effects of Glucagon on Hepatic Metabolism

Sponsor: Adrian Vella

View on ClinicalTrials.gov

Summary

Whether impaired postprandial glucagon suppression in prediabetes and T2DM is an attempt to overcome resistance to glucagon's actions on hepatic AA catabolism, a defect in α-cell function, or a combination of both are important, unanswered questions. NAFLD is associated with T2DM risk and impaired insulin action. Unfortunately, it is unclear if glucagon resistance is caused by obesity, hepatic steatosis or both. The experiments outlined will determine if glucagon's actions on hepatic amino acid catabolism and EGP interact with hepatic lipid metabolism in lean and obese subjects with and without T2DM (and with varying degrees of hepatic steatosis).

Key Details

Gender

All

Age Range

25 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

21

Start Date

2022-10-20

Completion Date

2026-03-31

Last Updated

2026-03-05

Healthy Volunteers

Yes

Interventions

DRUG

Glucagon response study

Please see information in group descriptions

Locations (1)

Mayo Clinic in Rochester

Rochester, Minnesota, United States